Hepatitis Test Solution Diagnosis Market Research Report - Global Forecast till 2027

Global Hepatitis Test Solution Diagnosis Market Research Report: Information by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C  and others), Type of Technology [Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User (Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6012-HCR | February, 2021 | Region : Global

Market Scenario


Hepatitis Test Solution Diagnosis Market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 2,659.38 Million in 2018 and is projected to register a 4.4% CAGR over the forecast period.


Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.


However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.


Segmentation


Global Hepatitis Test Solution Diagnosis Market is segmented based on disease type, type of technology, end user, and region.


Based on disease type, the global hepatitis test solution diagnosis market is further segmented into hepatitis A, hepatitis B, hepatitis C, and others.


Based on the type of technology, the hepatitis test solution diagnosis market at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.


Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others


The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The hepatitis test solution diagnosis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hepatitis test solution diagnosis market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hepatitis test solution diagnosis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hepatitis test solution diagnosis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hepatitis Test Solution Diagnosis Market Share (%), by Region, 2018  Hepatitis Test Solution Diagnosis Market


Sources: MRFR Analysis


The Americas dominated the hepatitis test solution diagnosis market, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.


Europe is expected to be the second-largest region in the hepatitis test solution diagnosis market, owing to the growing detection of hepatitis virus cases in the region.


The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body’s response to the hepatitis virus.


Thus, the hepatitis test solution diagnosis market in APAC is expected to hold the third-largest share during the forecast period.


The Middle East & Africa is expected to hold the least share of the hepatitis test solution diagnosis market during the forecast due to the slow economic development, especially in Africa.


Key Players


Some of the Key Players operating in the Global Hepatitis Test Solution Diagnosis Market are Abbott, Biomérieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.


Market Segmentation


Global Hepatitis Test Solution Diagnosis Market, by Disease Type



  • Hepatitis A

  • Hepatitis B

  • Hepatitis C

  • Others


Global Hepatitis Test Solution Diagnosis Market, by Type of Technology



  • Nucleic Acid Testing (NAT)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Rapid Diagnostic Tests (RDT)

  • Chemiluminescence Immunoassay (CLIA)

  • Genotyping

  • Others


Global Hepatitis Test Solution Diagnosis Market, by End User



  • Hospitals

  • Diagnostic Laboratories

  • Blood Banks

  • Research institutes

  • Others


Intended Audience



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers

Table of Contents


Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Assumptions

2.4 Limitations

Chapter 3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

Chapter 4. Market Dynamics

4.1 Overview

4.2 Drivers

4.3 Restraints

4.4 Opportunities

4.5 Pipeline Analysis

4.5 Macroeconomic Indicators

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

Chapter 6. Global Hepatitis Test Solution Diagnosis Market, by Disease Type

6.1 Overview

6.2 Hepatitis A

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Hepatitis B

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Hepatitis C

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027


Chapter 7. Global Hepatitis Test Solution Diagnosis Market, by Type of Technology

7.1 Overview

7.2 Nucleic Acid Testing (NAT)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Enzyme-Linked Immunosorbent Assay (ELISA)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Rapid Diagnostic Tests (RDT)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Chemiluminescence immunoassay (CLIA)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Genotyping

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Other

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Hepatitis Test Solution Diagnosis Market, by End User

8.1 Overview

8.2 Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostic Laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Blood Banks

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Research institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Hepatitis Test Solution Diagnosis Market, by Region

9.1 Overview

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Overview

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11 Company Profiles

11.1 Abbott

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financial Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategies

11.2 Biomérieux Sa

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 Bio-Rad Laboratories, Inc.

11.4 Danaher

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.6 Key Strategies

11.5 DiaSorin S.p.A.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategies

11.6 Miraca Holdings Inc. (Fujirebio, Inc.)

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Grifols

11.7.1 Company Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 Onsite Lab Holding AG (MedMira, Inc.)

11.8.1 Company Overview

11.8.2 Product Overview

11.8.3 Financial Overview

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 Qiagen

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial Overview

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 Roche Holding AG (Roche Diagnostics)

11.10.1 Company Overview

11.10.2 Product Overview

11.10.3 Financial Overview

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 Siemens (Siemens Healthineers)

11.11.1 Company Overview

11.11.2 Product Overview

11.11.3 Financial Overview

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.6 Key Strategies11.12 Sandoz International GmbH

11.12.1 Company Overview

11.12.2 Product Overview

11.12.3 Financial Overview

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

11.13 Others

Chapter 12 Appendix


LIST OF TABLES

TABLE 1. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SYNOPSIS, 2020-2027

TABLE 2. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET ESTIMATES AND FORECAST, 2020-2027 (USD MILLION)

TABLE 3. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 4. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 5. GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 7. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 8. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 9. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 10. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 11. US: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 13. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 14. CANADA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 15. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 16. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 17. LATIN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 18. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 19. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 20. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 21. WESTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 22. WESTERN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 23. WESTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24. EASTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 25. WESTERN AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 26. EASTERN EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 27. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 28. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 29. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 30. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 31. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY TYPE OF TECHNOLOGY, 2020-2027 (USD MILLION)

TABLE 32. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1. RESEARCH PROCESS

FIGURE 2. SEGMENTATION OF THE GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET

FIGURE 3. MARKET DYNAMICS OF THE GLOBAL HEPATITIS TEST SOLUTION DIAGNOSIS MARKET

FIGURE 4. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY TYPE, 2020

FIGURE 5. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY END USER, 2020

FIGURE 6. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY REGION, 2020

FIGURE 7. NORTH AMERICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 8. EUROPE: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 9. ASIA-PACIFIC: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY COUNTRY, 2020

FIGURE 10. MIDDLE EAST & AFRICA: HEPATITIS TEST SOLUTION DIAGNOSIS MARKET SHARE, BY REGION, 2020

FIGURE 11. HEPATITIS TEST SOLUTION DIAGNOSIS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 12. ABBOTT: KEY FINANCIALS

FIGURE 13. ABBOTT: SEGMENTAL REVENUE

FIGURE 14. ABBOTT: REGIONAL REVENUE

FIGURE 15. BIOMÉRIEUX SA: KEY FINANCIALS

FIGURE 16. BIOMÉRIEUX SA: SEGMENTAL REVENUE

FIGURE 17. BIOMÉRIEUX SA.: REGIONAL REVENUE

FIGURE 18. BIO-RAD LABORATORIES, INC.: KEY FINANCIALS

FIGURE 19. BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE

FIGURE 20. BIO-RAD LABORATORIES, INC: REGIONAL REVENUE

FIGURE 21. DANAHER: KEY FINANCIALS

FIGURE 22. DANAHER: SEGMENTAL REVENUE

FIGURE 23. DANAHER: REGIONAL REVENUE

FIGURE 24. DIASORIN S.P.A: KEY FINANCIALS

FIGURE 25. DIASORIN S.P.A: SEGMENTAL REVENUE

FIGURE 26. DIASORIN S.P.A: REGIONAL REVENUE

FIGURE 27. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): KEY FINANCIALS

FIGURE 28. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): SEGMENTAL REVENUE

FIGURE 29. MIRACA HOLDINGS INC. (FUJIREBIO, INC.): REGIONAL REVENUE

FIGURE 30. GRIFOLS: KEY FINANCIALS

FIGURE 31. GRIFOLS: SEGMENTAL REVENUE

FIGURE 32. GRIFOLS: REGIONAL REVENUE

FIGURE 33. ONSITE LAB HOLDING AG (MEDMIRA, INC.): KEY FINANCIALS

FIGURE 34. ONSITE LAB HOLDING AG (MEDMIRA, INC.): SEGMENTAL REVENUE

FIGURE 35. ONSITE LAB HOLDING AG (MEDMIRA, INC.): REGIONAL REVENUE

FIGURE 36. QIAGEN: KEY FINANCIALS

FIGURE 37. QIAGEN: SEGMENTAL REVENUE

FIGURE 38. QIAGEN: REGIONAL REVENUE

FIGURE 39. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): KEY FINANCIALS

FIGURE 40. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): SEGMENTAL REVENUE

FIGURE 41. ROCHE HOLDING AG (ROCHE DIAGNOSTICS): REGIONAL REVENUE

FIGURE 42. SIEMENS (SIEMENS HEALTHINEERS): KEY FINANCIALS

FIGURE 43. SIEMENS (SIEMENS HEALTHINEERS): SEGMENTAL REVENUE

FIGURE 44. SIEMENS (SIEMENS HEALTHINEERS): REGIONAL REVENUE

FIGURE 45. SANDOZ INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 46. SANDOZ INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 47. SANDOZ INTERNATIONAL GMBH: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.